Chronic Hepatitis Delta Virus (HDV) Infection – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Chronic Hepatitis Delta Virus (HDV) Infection Market Outlook

Thelansis’s “Chronic Hepatitis Delta Virus (HDV) Infection Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Hepatitis Delta Virus (HDV) Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Hepatitis Delta Virus (HDV) Infection Overview

Hepatitis Delta is the most severe form of viral hepatitis in humans and is caused by infection with the hepatitis delta virus (HDV). HDV is the only virus in the genus Deltaviridae. It is not classified as a viral family because it is a unique virus dependent on HBV. The HBV-dependent replication of HDV produces two forms of an RNA-binding protein known as the long and small delta antigens (Ag). The host cell provides all other proteins needed for the replication, especially the RNA-directed RNA polymerase activity. Thus, it can only cause disease in individuals who carry HBV. HDV infection is majorly transmitted via the parenteral route through exposure to blood or blood products. The hepatitis delta virus expresses only one protein, the hepatitis delta antigen (HDAg), which comprises a nucleocapsid-like structure with the genome. There are two forms of HDAg: small and large. Together, these and the single-stranded RNA genome are surrounded by a lipid envelope embedded with HBV-derived surface antigen (HBsAg) proteins.

• The incidence of disease increases from the age of 40 years, reaches a peak by 50-59 years and declines a little by the age of 70 years.
• HDV was present worldwide, and its local prevalence was a function of the prevalence of HBV. Approximately 5% of HBsAg carriers were estimated to be infected with HDV worldwide.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: